The CRED Biodiagnostic group have established a solid reputation in evaluation of diagnostics technologies, in Research, and in development and application of technologies and methodologies.

The activities of Biodiagnostic group are interested in development of innovative procedures in order to optimise the use and the cost of the diagnostic tests and equipment for use in patient diagnosis and patient management.

• Evaluation of new diagnostic assays and equipments;

• Multisites clinical evaluations;

• Research and development of new markers for use in patient diagnosis and patient management;

• Study on the impact of diagnostic tests on care efficiency;

• Study on cost-effectiveness and pharmacoeconomy;

• Implication in education and training.

Several research projects covering several fields are currently in development :

• Study the potential use of platelet activation as early marker of diagnosis/detection of coronary coronary syndrome, for monitoring of antiplatelet therapy and for evaluation of the cost-effectiveness of using this diagnostic test to support the judicious choice of antiplatelet therapy.

• Study the relationship between the inflammation (CRP), necrosis (troponins), homodynamic stress (BNP) and thrombosis (platelet activation) markers in patients with acute coronary syndrome.

• Study of diagnostic and management strategies for heart failure in order to elaborate a decisional model to analyse the use of the diagnostic test, BNP, for the identification of the best cost-effectiveness strategy.

• Development of automated technique to measure cortisol in saliva. Potential use of salivary cortisol as marker of Cushing diseases and stress.

• Evaluation of suspected interference caused by an antibody in immunoassay for specimens where the results are different from the patient clinical conditions. Online request is available to submit the interference cases.